HC Wainwright & Co. Maintains Buy on Relay Therapeutics, Lowers Price Target to $32
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns maintains a Buy rating on Relay Therapeutics (NASDAQ:RLAY) but lowers the price target from $46 to $32.
June 09, 2023 | 4:38 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Relay Therapeutics' price target has been lowered from $46 to $32 by HC Wainwright & Co. analyst Robert Burns, who maintains a Buy rating.
The news of HC Wainwright & Co. analyst Robert Burns maintaining a Buy rating on Relay Therapeutics (RLAY) is positive for the stock. However, the lowering of the price target from $46 to $32 may create uncertainty among investors, leading to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100